EDITOR'S DESK

  • WIB Profile: What Pharma Scientists Can Learn From A Specialty Drug Sales Rep
    WIB Profile: What Pharma Scientists Can Learn From A Specialty Drug Sales Rep

    When I first spoke with Laura McClung of Eli Lilly & Company about a Women in Bio (WIB) profile article, I almost wrote her off. Being involved in the sales force for Lilly, I initially felt she was too far outside the drug discovery process to contribute meaningful information to the readers of Outsourced Pharma. However, after having just one discussion with her, I immediately changed my mind.

    As McClung points out in this piece, many sales reps for Big Pharma have scientific or medical backgrounds. This makes them some of the most qualified individuals to advise doctors and clinicians on the medicines that will best meet the needs of patients. Their experience working with prescribers also makes them well qualified to provide feedback to those involved in the drug discovery process on what is needed by doctors and patients on the front lines.      

More From The Editor

CLINICAL PERSPECTIVES

  • BRIC Nations: Divergent Patterns in the Clinical Trials Landscape
    BRIC Nations: Divergent Patterns in the Clinical Trials Landscape

    The clinical trial landscape in BRIC countries is changing. Long heralded as a low-cost alternative to Western markets, Brazil, Russia, India and China are experiencing a shift in trial initiation by global sponsors.

  • FDA Safety Labeling Requirements
    FDA Safety Labeling Requirements

    Prior to 2007, the U.S. Food and Drug Administration’s labeling authority was limited; the agency could only request changes to the labeling of approved drug products. That changed, however, with the enactment of the Food and Drug Administration Amendments Act of 2007, in particular, section 505(o)(4). In that section, the FDA was given new authority to require safety labeling changes for approved drugs.

    This means the FDA can now order labeling changes if it becomes aware of new safety information that it believes should be included in the labeling of a drug. This article summarizes the FDA’s thinking in this regard, as indicated by its guidance released in recent weeks.

  • Gaining Greater Predictability, Control And Quality In Bioprocessing With Metabolic Biomarkers
    Gaining Greater Predictability, Control And Quality In Bioprocessing With Metabolic Biomarkers

    Biologics are an integral part of the landscape of current therapies as pipelines continue to fill with them. Due to their importance and this ever expanding pipeline, the demands continue to escalate due to cost pressure, competition, regulatory requirements, disposable systems, and biosimilars. To date, these demands arguably have primarily been met with empirical understanding. However, there is a critical need for new approaches, tools, and technologies to deliver deeper understanding beyond the empirical realm. By Dr. Kirk Beebe, Director of Application Science, Metabolon, Inc.

More Clinical Perspectives

FROM THE INDUSTRY EXPERTS

More From The Industry Experts

WHITE PAPERS AND CASE STUDIES

  • Preclarus™: Pilot Of In-House CRA And Cross-Functional Data Liaison (CDL)
    Preclarus™: Pilot Of In-House CRA And Cross-Functional Data Liaison (CDL)

    While conducting a high profile Phase III irritable bowel syndrome (IBS) program, PPD faced high screen failure rates and low enrollment. To ensure data currency and appropriate enrollment strategy adjustments, PPD had to work within the fixed price budget to develop the correct monitoring and data management strategy to meet the complex needs of this client’s program.

More White Papers & Case Studies

FEATURED SERVICES AND PRODUCTS

  • Late Phase Services
    Late Phase Services

    The success of a new product is judged by more than its promising clinical trial results. It needs to achieve its commercial objectives to justify initial investment. Chiltern Late Phase has focus in both local, national studies and large global programs. For example, Chiltern is currently performing registries from 100 patients to over 20,000 patients in a global setting.

     

  • eClinical Services
    eClinical Services

    BioClinica helps you get the most from your clinical data by combining best-in-class eClinical technology with expert data management and experience in almost 2000 electronic trials to date.

  • Off-The-Shelf Insulated Shipping Containers
    Off-The-Shelf Insulated Shipping Containers

    Sonoco ThermoSafe® Certis Qualified Shipping Containers deliver ultimate protection for your temperature-sensitive pharmaceuticals and biological specimens, meeting the toughest ambient profiles of any premium shipper in the industry.

  • uCTMS - Clinical Trial Management System
    uCTMS - Clinical Trial Management System

    DATATRAK’s Clinical Trial Management System, uCTMS, improves visibility for executive management and gives clinical operations teams more control of their pipeline.

  • CFS InSite™
    CFS InSite™

    The CFS InSite™ technology platform, which serves as the backbone for CFS Clinical’s investigator payment and study startup services, is designed with extensive data collection capabilities at an enterprise level.

  • CoSign Digital Signatures
    CoSign Digital Signatures

    Strict regulations, such as the FDA's 21 CFR part 11, require organizations in the life sciences industry to guarantee the authenticity, integrity and confidentiality of electronic records.

  • Preformulation & Formulation Development
    Preformulation & Formulation Development

    Patheon can structure a highly efficient, fully integrated early development program that can accelerate your project to First Time In Man studies and beyond. Whether your goal is to out license or follow through to commercialization, Patheon will also help you to quickly develop a formulation that achieves manufacturability and maximizes value.

  • Early Patient Clinical Studies
    Early Patient Clinical Studies Acquire robust Proof-of-Concept (PoC) data for your targeted populations with the Covance Early Clinical Development (ECD) specialists. The very nature of PoC studies requires cultivation to tease out excellences.
More Featured Services & Products

CRO LEADERSHIP AWARD

                                       
Life Science Leader developed the CRO Leadership Awards based on industry leading research conducted by Nice Insight. This award helps pharma and biopharm companies focus on potential partners who can handle their projects and are considered reputable in the industry. Click on the logo above to visit this year’s winners.

ABOUT CLINICAL LEADER

Welcome to Clinical Leader, the premier online community that helps streamline clinical research by connecting trial sponsors and cutting edge service providers. Clinical Leader is part of the Life Science Connect media group. The vision of Life Science Leader and Life Science Connect is to help facilitate connections and foster collaborations in pharmaceutical and medical device development to find ways to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute.

Visitors are enriched with valuable information on CRO, Pre-Clinical Contract Research Organization, Bio-Analytical Contract Research Organization, Clinical Contract Research Organization, Pharmacovigilance, Clinical Data Management, Electronic Patient Reported Outcomes (ePRO), Point-of-Care Testing (POCT), Patient Recruitment, Electronic Data Capture (EDC), Clinical Trials Management Systems (CTMS) and more that can improve your business and make it more profitable.

Please take a moment to join our community and discover the benefits of your free membership.

Newsletter Signup
Newsletter Signup

PREMIER SERVICE PROVIDER

CLINICAL LEADER WEBINARS

  • Digital Signatures: Enabling Compliant Collaboration and Streamlined Corporate Governance

    In this webinar, we’ll focus on the middle office where life sciences organizations can achieve tangible operational improvements and cost savings.

  • Adaptive Trials In Oncology Research Webinar

    Adaptive trial design is critical in all phases of oncology drug development and helps overcome many hurdles of traditional study design. In a recent webinar, PPD’s Dirk Reitsma, M.D., vice president, global product development, and Niklas Morton, vice president, global biostatistics, programming and medical writing, analyzed the incorporation of adaptive trial design in oncology trials. They were joined by Scott Berry, Ph.D., president and senior statistical scientist with Berry Consultants, to assess the early decision making benefits that are critical to the decreasing drug development time and providing increased benefit to patients.

  • Will BRIC be the Savior for the Life Sciences and Medical Devices Sector?

    Will BRIC be the Savior for the Life Sciences and Medical Devices Sector?  Discover key lessons from the field and best practices vital to reap rewards from these countries during Frost & Sullivan’s complimentary webinar. The briefing will benefit any senior manager in the corporate strategy or global marketing areas that focuses on emerging markets, as well as any healthcare company looking to explore BRIC countries.

  • New Indications For Existing Medical Entities

    This webinar will take a critical view at the diverse technologies that have been proposed for repositioning. 

More From Clinical Leader Webinar

 UPCOMING TRAINING COURSES

Serialization Preparedness – What you Must Know for Bullet-Proof Programs

August 12, 2014
1pm-2:30pm EDT, Online Training

Introduction to Biostatistics: Hypothesis Testing

August 14, 2014
1pm-3pm EDT, Online Training

Root Cause Analysis for GCP – A Risk Action Plan Guide

August 19, 2014
1pm-3pm EDT, Online Training

Lyophilization - An Introduction to the Scientific Principles

August 20, 2014
1pm-2:30pm EDT, Online Training
More Upcoming Courses

CLINICAL BULLETIN BOARD

According to the WHO, over 150m people worldwide, are chronically infected with HCV, with 3 to 4m new infections occurring each year. Together they represent a multibillion dollar market for any successful new drug candidate, with Hepatitis C having the most promising products in development.

 CLINICAL EVENTS

Serialization Preparedness – What you Must Know for Bullet-Proof Programs

August 12, 2014
1pm-2:30pm EDT, Online Training
Price:  $299 - Introductory Rate

Introduction to Biostatistics: Hypothesis Testing

August 14, 2014
1pm-3pm EDT, Online Training
Price:  $349 - Introductory Rate

Root Cause Analysis for GCP – A Risk Action Plan Guide

August 19, 2014
1pm-3pm EDT, Online Training
More Events....